Anti-metastatic effect of metformin via repression of interleukin 6-induced epithelial-mesenchymal transition in human colon cancer cells.

Anti-metastatic effect of metformin via repression of interleukin 6-induced epithelial-mesenchymal transition in human colon cancer cells.

Metformin, a first-line drug used to treat type 2 diabetes, has also been shown to have anticancer effects against a variety of malignancies, including colorectal cancer. Although inhibition of the mTOR pathway is known to be the most important mechanism for the antitumor effects of metformin, other...

Full description

Bibliographic Details
Main Authors: Sanghee Kang, Bo Ram Kim, Myoung-Hee Kang, Dae-Young Kim, Dae-Hee Lee, Sang Cheul Oh, Byung Wook Min, Jun Won Um
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC6181375?pdf=render

Similar Items

Similar Items